Cost-effectiveness of bortezomib for multiple myeloma: a systematic review.

To review published cost-effectiveness analyses (CEA) assessing bortezomib (BTZ) for multiple myeloma (MM) and explore possible bias affecting the cost-effectiveness of BTZ.